These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9376202)

  • 1. Aromatase inhibitors for breast cancer--further progress.
    Rubens RD
    Eur J Cancer; 1997 Jun; 33(7):989-90. PubMed ID: 9376202
    [No Abstract]   [Full Text] [Related]  

  • 2. Aromatase inhibitors come of age.
    Dowsett M
    Ann Oncol; 1997 Jul; 8(7):631-2. PubMed ID: 9296213
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aromatase inhibitors].
    Feutrie ML; Bonneterre J
    Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aromatase inhibitors].
    Mauriac L; Bonneterre J
    Bull Cancer; 2000 Dec; 87 Spec No():5. PubMed ID: 11250603
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
    Pérez N; Borja J
    J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy for breast cancer.
    CA Cancer J Clin; 2005; 55(3):195-8. PubMed ID: 15890641
    [No Abstract]   [Full Text] [Related]  

  • 9. Third generation aromatase inhibitors in metastatic breast cancer patients failing tamoxifen. Randomized comparisons with megestrol acetate: a critical review.
    Bonte J
    Eur J Gynaecol Oncol; 2000; 21(6):555-9. PubMed ID: 11214609
    [No Abstract]   [Full Text] [Related]  

  • 10. Future directions in endocrine treatment of advanced breast cancer.
    Bland KI
    Ann Surg Oncol; 1999 Dec; 6(8 Suppl):14S-16S. PubMed ID: 10619455
    [No Abstract]   [Full Text] [Related]  

  • 11. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
    Murray R; Pitt P
    Breast Cancer Res Treat; 1995 Sep; 35(3):249-53. PubMed ID: 7579495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
    Frost VJ; Helle SI; Lønning PE; van der Stappen JW; Holly JM
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2216-21. PubMed ID: 8964854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors.
    Brodie AM; Santen RJ
    Crit Rev Oncol Hematol; 1986; 5(4):361-96. PubMed ID: 3094971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with aromatase inhibitors in the treatment of advanced breast cancer.
    Höffken K
    Cancer Treat Rev; 1993 Apr; 19 Suppl B():37-44. PubMed ID: 8481933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors in the treatment of advanced breast cancer.
    Miller WR
    Cancer Treat Rev; 1989 Jun; 16(2):83-93. PubMed ID: 2527597
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aromatase inhibitors: a review of clinical trials].
    Kerbrat P; Lefeuvre C
    Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients.
    Anker GB; Refsum H; Ueland PM; Johannessen DC; Lien EA; Lonning PE
    Clin Chem; 1999 Feb; 45(2):252-6. PubMed ID: 9931048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pivotal trials of letrozole: a new aromatase inhibitor.
    Smith IE
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):41-4. PubMed ID: 9556791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Perspectives of breast cancer from the ECCO-9 and from the 15th National Convention of Experimental and Clinical Oncology].
    Tumori; 1997; 83(6):979-82. PubMed ID: 9537919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.